Background. Dengue viruses (DENVs) infect >300 million people annually, causing 96 million cases of dengue disease and 22 000 deaths [1] . A safe vaccine that protects against DENV disease is a global health priority [2] .
rash, and 22 000 die from infection [1] . The 4 serotypes of DENV (DENV-1-4) are transmitted by Aedes mosquitoes and have spread widely in recent decades [3] [4] [5] [6] . The first infection with DENV induces protective homotypic immunity to the homologous DENV but increases the risk of severe disease during subsequent infection with a heterologous DENV [7] [8] [9] [10] [11] . Development of a safe vaccine that provides durable protection from dengue disease is a global health priority.
A recombinant live attenuated tetravalent dengue vaccine (TDV) candidate was developed by genetic engineering on the basis of the attenuated DENV-2 PDK-53 strain [12] . A single dose of DENV-2 PDK-53 was well tolerated and highly immunogenic after administration to 25 volunteers [13] [14] [15] . Whole-genome sequencing and viral genetic characterization demonstrated that the mutations necessary and sufficient for attenuation of DENV-2 PDK-53 lie in the 5′ noncoding region (NCR) and in nonstructural proteins 1 and 3 (NS1 and NS3) [16] . TDV (termed "DENVax" in some previous publications) contains the DENV-2 PDK-53 complementary DNA clone-derived TDV-serotype 2 (TDV-2) and 3 TDV-3 chimeric vaccine viruses, TDV-1, TDV-3, and TDV-4, that were engineered by replacing the TDV-2 premembrane and envelope genes with the respective genes from DENV-1 16007, DENV-3 16562, or DENV-4 1036 [17] [18] [19] . Cynomolgus macaques seroconverted to DENV-1-4 after 2 doses of TDV and were protected from viremia after challenge with each of the 4 wild-type DENV serotypes [20, 21] . We evaluated the safety and immunogenicity of 2 different formulations of TDV in healthy, flavivirus-naive adults in the United States; a similar study was conducted in Colombia [22] .
MATERIALS AND METHODS

Ethics Statement
The study was approved by the Saint Louis University Institutional Review Board. Written informed consent was obtained from volunteers, in accordance with the Code of Federal Regulations (21 CFR 50) and International Conference on Harmonization guidelines for good clinical practice (ICH E6). An independent safety monitoring committee (SMC) convened prior to the start of the study under the auspices of the Saint Louis University Vaccine Treatment Evaluation Unit (VTEU) reviewed all safety data periodically.
Trial Design
This phase 1, randomized, double-blinded, placebo-controlled study (clinical trials registration NCT01110551) conducted at the Saint Louis University VTEU evaluated the safety and immunogenicity of low-dose or high-dose formulations of TDV given in 2 doses 90 days apart by either subcutaneous or intradermal injection. The primary outcome was safety, characterized as the number of volunteers in each group with local or systemic vaccine reactogenicity and vaccine-associated adverse events. Secondary outcomes included (1) viremia, measured as the number of volunteers with detectable TDV RNA, further characterized by duration, mean peak viral RNA titer, and detection of infectious virus; and (2) geometric mean titer (GMT) of neutralizing antibodies to DENV-1-4 through 30 days after the second dose. The antibody response was also measured by the number of subjects who seroconverted to each DENV serotype. After the second dose, we also determined the presence of detectable viral RNA and increases in neutralizing antibody titers to each DENV [23, 24] .
Four cohorts (18 subjects each) were randomly assigned to receive vaccine or placebo in a 2:1 ratio (Figure 1 ). The first 2 subjects in the low-dose and high-dose cohorts received open-label vaccine and were followed for 14 days, and the SMC evaluated safety before enrollment of the remainder of the group. All subjects in the low-dose group received the first dose, were followed for 21 days, and the SMC reviewed safety before enrollment of the high-dose group started.
Study Population
Healthy adult male and nonpregnant female volunteers aged 18-45 years who lived in the United States were enrolled. Health was determined by medical history, physical examination, laboratory evaluation (hematologic analysis, chemistry analysis, coagulation analysis, and urinalysis), and electrocardiography. Subjects were eligible if they tested negative for serum hepatitis B virus surface antigen and antibodies to DENV, West Nile virus, hepatitis C virus, and human immunodeficiency virus. Volunteers were excluded if they had a history of receiving a flavivirus vaccine, a history of a flavivirus infection, and a recent history of or planned travel to a dengue-endemic area. Female volunteers had negative results on pregnancy tests at screening and before each dose of vaccine and agreed to use contraception.
Vaccine
The low-dose formulation (subcutaneous and intradermal) contained 8 × 10 3 plaque-forming units (PFU) of TDV-1, Because intradermal administration via Mantoux injection using a needle and syringe resulted in a wheal, both volunteers and study personnel were blinded to treatment but not to the route of administration.
Clinical Procedures and Safety Evaluation
Subjects were monitored for 60 minutes after administration, and recorded daily oral temperature and any local or systemic reactogenicity for 14 days. Clinical assessments were performed on days 0, 2, 4, 5, 7, 9, 11, 14, 21, and 30; the same schedule was followed after the second administration. Safety laboratory analyses were performed on days 7, 14, 21, and 60 and again after the second administration. Subjects were seen on days 180 and 270 for a final assessment. All subjects who received 1 dose of vaccine or placebo were included in the safety analysis, and all subjects who received 2 doses of vaccine and underwent assessment on day 120 were included in the immunogenicity analysis.
Adverse Events
All adverse events and abnormal safety laboratories were graded for intensity and relationship to vaccine. Serious adverse events were defined in accordance with 21 CFR 312.32. All adverse events were followed to resolution or stabilization.
Quantitation and Analysis of TDV-Associated Viremia
Serum for measuring TDV viremia was obtained on days 0 (before vaccination), 2, 4, 5, 7, 9, 11, and 14; the same sampling was repeated for the second administration. TDV RNA was measured by quantitative revere-transcription polymerase chain reaction (qRT-PCR) analysis at the Illinois Institute of Technology Research Institute (Chicago, Illinois). Viral RNA was extracted [20] and analyzed by duplex qRT-PCR with vaccine virus-specific envelope gene primers [25] and Taqman probes (sequences are available upon request). Serially diluted in vitro-transcribed viral RNAs from TDV complementary DNA (cDNA) subclones were amplified in parallel as standard curves [25] . Each sample was tested in 3 replicates. The lower quantifiable limit of the qRT-PCR was 3.66 log 10 genome equivalents/mL for each DENV serotype. Serial dilutions of serum samples with detectable viral RNA were plated on Vero cells, and the presence and type of infectious virus was determined by immunostaining with DENVspecific monoclonal antibodies 1F1 (for DENV-1), 3H5 (for DENV-2), 8A-1 (for DENV-3), and 1H10 (for DENV-4) [21] . Sensitivity was 1 log immuno-focus-forming units (iFFU)/mL. Samples with infectious virus underwent spot sequencing to monitor for reversion of attenuation determinants. Three cDNA fragments were amplified from viral RNA and sequenced Data are no. (%) of subjects, unless otherwise indicated.
using DENV-2-specific primers [25] . Each fragment contained one of the 3 attenuation loci (nucleotide 57 in the 5′ NCR, nucleotide 2579 for NS1-53-Asp, and nucleotide 5270 for NS3-250-Val) [16] . Sequencing was conducted on an ABI 3130xl sequencer and analyzed by DNAStar Lasergene 11 software.
Serologic Assessment
Serum specimens for measurement of neutralizing antibodies were obtained on days 0, 14, 30, 60, 90, 104, and 120. Neutralizing antibodies were measured using a previously described 50% immuno-focus-reduction neutralization test (FRNT 50 ) [22] , which is similar to the 50% plaque-reduction neutralization test, and accorded with World Health Organization guidelines [26] . Heat-inactivated serum samples underwent 2-fold serial dilution, starting at a 1:5 dilution, and were incubated with an equal volume of DENV-1 16007, DENV-2 16681, DENV-3 16562, or DENV-4 1036 overnight at 4°C (the lowest final serum dilution was 1:10). Virus-serum mixtures were inoculated in triplicate onto confluent Vero cells in a 96-well plate. After adsorption for 1.5 hours at 37°C, cells were overlaid with methylcellulose medium and incubated for 2-3 days, depending on the DENV. After removal of the overlay, washing, fixation, and immunostaining, the viral foci were quantified using an enzyme-linked immunospot reader. Back titration of the input virus was included in each assay. The FRNT 50 was defined as the highest reciprocal serum dilution titer that reduced the number of input viral foci by ≥50%. Samples with a FRNT 50 value of < 10 were considered seronegative and assigned a FRNT 50 value of 5 for calculation of GMT, and those with antibody titers of ≥10 were considered seropositive, in accordance with other dengue vaccine trials [26, 27] . Seroconversion was defined as either an initially seronegative subject becoming seropositive after vaccination or as a ≥4-fold rise in titer in initially seropositive subjects.
Data Analysis
Significant differences in the frequency of reactogenicity or adverse events between vaccinees and placebo recipients or between dose groups and administration routes were determined using the Fisher exact test, with 2-tailed P values. The KruskalWallis test was used to compare GMTs of neutralizing antibodies to each DENV. Statistical analyses were performed using SAS, version 9.2.
RESULTS
Demographic Characteristics and Study Enrollment
Of 170 subjects screened, 72 were enrolled ( Figure 1 ). There were no significant differences in demographic parameters between vaccinees and placebo recipients or between dose groups (Table 1) . Fifty-seven subjects (79%) received the second dose. The 15 subjects who did not were similarly distributed between treatment groups (Figure 1 ). Reasons for discontinued vaccinations were as follows: 4 subjects were lost to follow-up, 3 withdrew because they could not attend all visits, 5 had non-vaccine-related adverse events, and 3 were withdrawn because of noncompliance with the protocol. One additional subject, who received 2 doses, was lost to follow-up before day 120. 
Safety and Reactogenicity
Both formulations of vaccine were generally well tolerated (Table 2) . Seven vaccinees (14.6%) but no placebo recipients reported transient fever (maximum temperature, 37.8°C-39.1°C) after the first dose (P = .087). Vaccinees reporting fever were evenly distributed among the 4 groups. Two subjects in the high-dose group had fever for up to 2 days with concurrent TDV-3 viral RNA and infectious virus. One reported mild headache, nausea, and fatigue, and the other reported mild headache, fatigue, myalgia, and photophobia. Vaccinees were significantly more likely to report pain (52% vs 17%; P = .005) or erythema (73% vs 25%; P = .0001) at the injection site than placebo recipients. Induration (91.7% vs 12.5%; P < .0001) and pruritus (50% vs 8.3%; P = .0034) were more common after intradermal vaccination than after subcutaneous vaccination. There was no difference in the incidence of headache, rash, photophobia, eye pain, myalgia, arthralgia, fatigue, nausea, or vomiting between vaccinees and placebo recipients. Most reactogenicity was mild and resolved within 1 day. Nine low-dose vaccinees (37.5%) and 6 high-dose vaccinees (25%) reported a mild treatment-associated adverse event, as did 4 placebo recipients (16.7%). Three vaccinees and 3 placebo recipients reported a moderate treatment-associated adverse event. Three vaccinees had mild transient asymptomatic leukopenia (minimum leukocyte count, 3300 cells/µL), and one had mild neutropenia (nadir neutrophil count, 1402 neutrophils/mm 3 ) and TDV-2 viral RNA. The 3 vaccinees were equally distributed between the low-dose and high-dose groups. One vaccinee with leukopenia also had an asymptomatic, mildly elevated alanine transaminase (ALT) level. No placebo recipients had elevated ALT levels or leukopenia. No vaccinees had thrombocytopenia or coagulation abnormalities. Four vaccinees and 1 placebo recipient reported serious adverse events; none were deemed related to the vaccine by the investigator or the SMC.
TDV Replication and Viremia
TDV viral RNA was detected after the first immunization in 11 low-dose recipients (46%) and 19 high-dose recipients (79%; P = .036; Abbreviations: CI, confidence interval; GMT, geometric mean titer; TDV, tetravalent dengue vaccine. a Day 120 analysis included only subjects who received 2 doses of TDV and were followed up through day 120.
b One subject was excluded from the analysis because of missing day 90 data.
c One subject was excluded from the analysis because of missing baseline data.
Phase 1 Clinical Trial of TDV • JID 2015:212 (1 October) • 1037 peak levels of TDV-2, TDV-3, and TDV-4 viral RNA were 4.1, 3.8, and 4.4 log 10 genome equivalents/mL, respectively. The maximum levels of TDV-2, -3, and -4 viral RNA were 4.8, 4.3, and 4.4 log 10 genome equivalents/mL, respectively. There was no significant difference between low-dose and high-dose recipients in the mean peak or maximum levels of any TDV viral RNA. The duration of TDV viral RNA detection varied from 1 to 11 days. The duration of TDV-2 detection was longer in the high-dose group (mean minimum duration, 4.2 vs 1.6 days; P = .02). One low-dose recipient and 5 high-dose recipients had TDV-2 and TDV-3 viral RNA; no other subjects showed evidence of replication of >1 TDV component. No viral RNA was detected after the second dose. Four low-dose recipients and 7 high-dose recipients (23% of vaccinees) had detectable infectious TDV-2 viremia (mean titer, 1.22 log 10 iFFU/mL; range, 1.0-1.6 log 10 iFFU/mL). Two lowdose recipients and 5 high-dose recipients (15% of vaccinees) had infectious TDV-3 viremia; (mean titer, 1.63 log 10 iFFU/ mL; range, 1.0-2.3 log 10 iFFU/mL). The titer in the subject with TDV-4 viremia was 3.11 log 10 iFFU/mL. No reversions were seen in the attenuation determinants at NS1-53 or NS3-250. Thirteen subjects (4 low-dose recipients and 9 high-dose recipients) demonstrated evidence of reversion of the attenuation locus at 5′ NCR-57; reversion was seen in TDV-2, TDV-3, and TDV-4. Mean viral titers for those with and those without the reversion were 1.49 log 10 iFFU/mL (range, 1-3.1 log 10 iFFU/mL) and 1.41 log 10 iFFU/mL (range, 1.3-2.0 log 10 iFFU/mL), respectively (P = not significant). There was no difference in the duration of viral RNA detection, reactogenicity, or rate of adverse events between subjects with and those without evidence of reversion at the 5′ NCR locus.
Serologic Response to DENV
Both vaccine formulations induced seroconversion rates of 46%-100% to each DENV serotype after 2 doses (Table 4) . Overall seroconversion rates and GMTs on day 120 were highest to DENV-2 (92.1% and a FRNT 50 of 292.8, respectively), followed by DENV-3 (86.8% and a FRNT 50 of 32.3, respectively),  DENV-1 (84.2% and a FRNT 50 of 54.1, respectively) , and DENV-4 (71.1% and a FRNT 50 of 15.0, respectively). There was a significant increase in GMT to DENV-1 (FRNT 50 , 21.6 vs 118.9; P = .0001) and DENV-2 (172.8 vs 460.1; P = .039, respectively) and a significant decrease in GMT to DENV-4 (FRNT 50 , 21.6 vs 11.0; P = .022) among high-dose recipients, compared with low-dose recipients. After 1 dose, 100% of high-dose recipients seroconverted to DENV-1, >90% seroconverted to DENV-2, >80% seroconverted to DENV-3, and ≥50% seroconverted to DENV-4. The second high dose numerically increased day 90 titers and/or seroconversion to DENV-1 and DENV-4. Overall, >70% of vaccinees seroconverted to DENV-1-4 after 2 doses. When subjects who did not receive the second dose were included in the analysis, seroconversion rates and GMTs on day 120 were comparable to those for subjects who received both doses (data not shown).
No subject had a 4-fold increase in FRNT 50 to DENV-2 after receipt of the second dose, indicating that 1 dose of TDV was sufficient to block replication of TDV-2 after the second administration (Table 5 ). Only 2 subjects (5.3%) had a 4-fold rise in titer to DENV-3 after the second dose. The greatest effect of the second dose was on titers to DENV-1 and DENV-4: 13 subjects (34.2%) and 16 subjects (42.1%), respectively, showed a ≥4-fold increase.
More than 90% of subjects who received 2 high-dose immunizations seroconverted to ≥3 DENV serotypes (indicative of a trivalent or tetravalent response), and all subjects who received 2 high-dose immunizations or 2 low-dose subcutaneous doses seroconverted to ≥2 DENV serotypes ( Table 6 ). The highest rate of seroconversion to all 4 DENV serotypes occurred in the intradermal high-dose group (80.0%) and the subcutaneous low-dose group (77.8%); however, there were no significant differences in the number of subjects with a tetravalent response between any of the groups. When subjects who had only 1 dose of vaccine were included in the analysis, >90% of highdose subjects had at least a trivalent response (data not shown). The second immunization increased the response a Seroconversion was defined as a conversion from a 50% immuno-focus-reduction neutralization titer (FRNT 50 ) of <10 after the first dose (measured on study 90) to a FRNT 50 of >10, and the increase in titer after the second dose (measured on study 120) was relative to the titer after the first dose (measured on study day 90). Data obtained after the second dose (on study day 120) were from subjects who received 2 doses of TDV and were followed through day 120. b One subject was excluded from the analysis missing data after Day 90 data.
rates of the total subjects to all 4 DENV serotypes from 50% to 62% and to ≥3 DENV serotypes from 77% to 85%.
DISCUSSION
In this phase 1, double-blinded, placebo-controlled study of 72 healthy, flavivirus-naive adults, 2 doses of TDV given 90 days apart were well tolerated and immunogenic, inducing neutralizing antibodies to ≥3 DENV serotypes in 85% of volunteers. Two subjects in the high-dose group had fever, coincident with infectious TDV-3 viremia, and 1 had symptoms compatible with a mild dengue-like illness after the first dose. No other subject reporting fever had detectable viral RNA. Vaccinees were more likely than placebo recipients to report pain or erythema at the injection site. Three vaccinees had mild transient asymptomatic leukopenia after the first dose, and 1 had a mildly elevated ALT level, which was also asymptomatic. No vaccine-associated serious adverse events occurred, and the majority of reported adverse events were mild. TDV-2 viral RNA and infectious virus were the most frequently observed of the 4 TDV components after the first dose, and TDV-2 also induced the highest neutralizing antibody titers and seroconversion rates. An anamnestic antibody response to TDV-2 was not seen in any subject after the second vaccination, indicating that a single dose of TDV induced an immune response [23, 24] that prevented replication of the attenuated TDV-2 after the second administration [23, 24] . The second dose increased seroconversion rates and titers to DENV-1 and DENV-4, inducing neutralizing antibodies to each of the 4 DENV serotypes in the majority of vaccinees, and 85% had responses to ≥3 DENV serotypes (Table 6 ). Despite the absence of detectable TDV-1 viral RNA, 100% of volunteers who received 2 doses in the high-dose groups developed neutralizing antibodies to DENV-1. In the high-dose groups, 100% of volunteers seroconverted to DENV-1 and DENV-2, and ≥82% seroconverted to DENV-3 (Table 4) . Further studies to determine whether these antibodies are type specific or cross-reactive are in progress. These findings are noteworthy, given the recent efficacy trial results (1 phase 2b and 2 phase 3 trials) of a recombinant live attenuated tetravalent dengue vaccine candidate (CYD-TDV) that showed moderate protective efficacy against fevers caused by DENV-2 (9.2%, 35.0%, and 42.3% in the 3 studies), partial protection against fevers caused by DENV-1 (55.6, 50.0%, and 50.3%) [28] [29] [30] , and higher levels of protection against fevers caused by DENV-3 (75.3%, 78.4%, and 74%) and DENV-4 (100%, 75.3%, and 77.7%) [27] [28] [29] . TDV viral RNA was observed in 83% of volunteers after the first vaccination but was not seen after the second administration. This finding is corroborated by the overall lower reactogenicity after the second dose. Similar protection from viremia after the second dose was observed in studies of another tetravalent dengue vaccine candidate [31] . In contrast, vaccine viremia persisted in some volunteers after the second and third dose of the CYD-TDV candidate [32, 33] . While TDV viral RNA and infectious viremia were more frequent and of longer duration in high-dose versus low-dose recipients, there was no increased rate of local or systemic reactogenicity or vaccine-related adverse events in the high-dose group.
The 2 attenuating determinants in the viral open-reading frame, NS1-53 and NS3-250 [16] , were stable in all subjects. Thirteen vaccinated subjects (27%) had evidence of reversion at the 5′ NCR-57 attenuating locus. Genetic-stability studies of these vaccine constructs have shown that the NS1-53 and NS3-250 loci were highly stable after multiple passages in Vero cells, while 5′ NCR-57 was more prone to reversion [25] . Previous studies have demonstrated that NS1-53 is the most significant attenuation determinant for the vaccine. Reversion of at least 2 of the 3 attenuation loci are required to reconstitute the wild-type phenotype [16] , and the combination of the NS1-53 and NS3-250 attenuation loci was sufficient to retain all attenuation phenotypes characterized in vitro and in vivo (in mice and mosquitoes) [16, 34] . These results further demonstrate that TDV retaining the NS1-53 and NS3-250 determinants is still sufficiently attenuated in humans, as there was no increase in viral titers, duration of viremia, reactogenicity, or adverse events in subjects with the reversion. This study represents one of 2 completed phase 1 trials conducted with TDV constructs in regions where dengue is not endemic [22] . The study populations in the US and Colombia trials differed significantly with respect to race and geographic locale. While there were minor differences in trial and assay methods, the outcomes were similar. Intradermal and subcutaneous administration of the TDV formulations was well tolerated and induced similar immune responses in both populations, validating the outcome of each.
In these phase 1 studies, TDV was administered in 2 doses 90 days apart, in contrast to 3 doses given 6 months apart for the candidate CYD-TDV vaccine [29, 33] . A 2-dose, 90-day schedule was chosen on the basis of preclinical studies [19, 20] . A 1-dose or 2-dose schedule may be more practicable and easier to ensure compliance in resource-limited settings or in the event of an outbreak [3, 35] and is more easily administered to travelers or military personnel [36] . Other dosing regimens for TDV are being evaluated in ongoing clinical trials. The decreased local reactogenicity of subcutaneous administration, combined with the higher seroconversion rates, higher neutralizing antibody titers, and induction of a trivalent or broader neutralizing antibody response in >90% of vaccinees suggest that subcutaneous delivery of the high-dose formulation warrants further development [37, 38] . Based on the results of this study and the Colombia trial [22] , further development of TDV, including studies in multiple age groups and in dengue-endemic and dengue-nonendemic countries, is in progress.
Notes
